Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03114540 · ClinicalTrials.gov registry record · Phase 1
Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT03114540 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 29 participants.
The verdict
NCT03114540, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
A Phase 1, multiple center, nonrandomized, open-label, parallel group study of a single oral dose of GBT440 administered in subjects with mild (Child-Pugh A), moderate (Child-Pugh B), or severe (Child-Pugh C) hepatic impairment disease and healthy subjects with normal hepatic function.
Interventions
- DRUG GBT440
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2017-03-17 |
| Est. Completion | 2018-03-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03114540
The ClinicalTrials.gov registry entry for NCT03114540 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GBT440 is the first listed.
NCT03114540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03114540 about?
NCT03114540 is a clinical study titled "Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment". A Phase 1, multiple center, nonrandomized, open-label, parallel group study of a single oral dose of GBT440 administered in subjects with mild (Child-Pugh A), moderate (Child-Pugh B), or severe (Child-Pugh C) hepatic impairment disease and healthy subjects with normal hepatic function.
What is the current status of trial NCT03114540?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2017-03-17. Estimated completion is 2018-03-22.
What interventions are being tested in trial NCT03114540?
The interventions under investigation include: GBT440 (DRUG).
Who is sponsoring clinical trial NCT03114540?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.